In-Vitro Evaluation of HIV/SARS-CoV-2 Co-Infection Mediated Proteomic Changes in Astrocytes and Pericytes Reveals Altered Signaling Pathways Associated With Neurodegenerative Disorders.

In-Vitro Evaluation of HIV/SARS-CoV-2 Co-Infection Mediated Proteomic Changes in Astrocytes and Pericytes Reveals Altered Signaling Pathways Associated With Neurodegenerative Disorders.

Publication date: Aug 01, 2026

Coronavirus disease 2019 (COVID-19) survivors frequently experience a wide range of symptoms known as post-acute sequelae of SARS-CoV-2 (PASC) or long COVID. Importantly, complications arising from microvascular dysfunction, blood-brain barrier (BBB) disruption, and chronic neuroinflammation have been implicated in driving PASC within the central nervous system (CNS), known as neuro-PASC. Notably, people with HIV (PWH), who suffer from chronic neuroinflammation, BBB impairment, and glial cell dysfunction, collectively known as neuro-HIV, are generally at higher risk of neuro-PASC. The overlap between neuro-PASC and neuro-HIV raises concerns that HIV and SARS-CoV-2 co-infection may exacerbate neurological dysfunctions among PWH. In this study, using an in-vitro cell culture model, we examine the effects of HIV and SARS-CoV-2 mono- and co-infection in microglia, astrocytes, and pericytes. Our results demonstrated that majority of brain cell types support SARS-CoV-2 replication, in the presence and absence of HIV infection. Furthermore, in both mono- and co-infected cells, there were varying degree of up- and downregulation of SARS-CoV-2 host cell entry factors, such as ACE2, TMPRSS2, NRP1, and TRIM28, and inflammatory cytokines including IL-6, TNF-α, and IL-1β. Moreover, conditioned media collected from HIV, SARS-CoV-2, and HIV/SARS-CoV-2 co-infected astrocytes and pericytes were shown to be neurotoxic. Additionally, proteomic analysis has revealed a unique set of proteins significantly up/down regulated in HIV/SARS-CoV-2 co-infected astrocytes and pericytes. The gene set enrichment analysis of these proteins indicates dysregulation of lipid, energy, and immune metabolism pathways linked to neurodegenerative disorders like Alzheimer’s, Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis. These in-vitro findings indicate that astrocytes and pericytes from HIV/SARS-CoV-2 co-infection exhibit altered protein expression profiles, implicating dysregulated signaling pathways associated with neurodegenerative dysfunction.

Open Access PDF

Concepts Keywords
Alzheimer ACE‐2
Astrocytes and pericytes
Coronavirus Astrocytes
Covid astrocytes
Neurodegenerative co‐infection
Coinfection
COVID-19
COVID‐19
HIV
HIV Infections
Humans
long‐covid
Microglia
microglia
Neurodegenerative Diseases
neuroHIV
PASC
Pericytes
Post-Acute COVID-19 Syndrome
Proteome
Proteome
Proteomics
SARS-CoV-2
SARS‐CoV‐2
Signal Transduction
Virus Replication

Semantics

Type Source Name
disease MESH Co-Infection
disease MESH Neurodegenerative Disorders
disease MESH Coronavirus disease 2019
disease MESH long COVID
disease MESH neuroinflammation
disease MESH HIV infection
pathway REACTOME HIV Infection
pathway REACTOME Metabolism
disease MESH Huntington’s disease
disease MESH amyotrophic lateral sclerosis
pathway KEGG Amyotrophic lateral sclerosis
disease MESH kos
disease MESH sid
disease MESH dys
pathway REACTOME Reproduction
drug DRUGBANK Angiotensin II
disease MESH Alzheimer’s Disease
disease MESH Neurocognitive Disorder
pathway KEGG Huntington disease
disease MESH MDM
disease MESH Middle East respiratory syndrome
disease MESH infection
disease MESH Parkinson’s Disease
disease MESH Severe acute respiratory syndrome
drug DRUGBANK Serine
disease MESH hypertension
disease MESH Cognitive impairment
disease MESH headache
disease MESH vertigo
disease MESH anosmia
disease MESH tinnitus
disease MESH dysautonomia
pathway REACTOME Immune System
disease MESH memory loss
disease MESH FBS
disease MESH strain
disease MESH PBS
disease MESH hpi
drug DRUGBANK Tretinoin
drug DRUGBANK Alteplase
drug DRUGBANK Sodium lauryl sulfate
disease MESH SDS
pathway REACTOME Digestion
drug DRUGBANK Flunarizine
disease MESH HCD
disease MESH MS2
drug DRUGBANK Methionine
drug DRUGBANK L-Asparagine
drug DRUGBANK L-Glutamine
drug DRUGBANK L-Lysine
drug DRUGBANK L-Cysteine
disease MESH included
disease MESH Death
disease MESH neuroblastoma
pathway REACTOME Pyruvate metabolism
pathway KEGG Oxidative phosphorylation
pathway REACTOME Glycolysis
pathway KEGG Tryptophan metabolism
drug DRUGBANK Taurine
pathway KEGG Circadian entrainment
pathway KEGG mTOR signaling pathway
pathway KEGG Glutathione metabolism
pathway KEGG Thiamine metabolism
pathway KEGG Glycerolipid metabolism
pathway KEGG Hedgehog signaling pathway
pathway REACTOME Inositol phosphate metabolism
pathway REACTOME Sphingolipid metabolism
drug DRUGBANK Thiamine
pathway KEGG Insulin signaling pathway
pathway KEGG MAPK signaling pathway
pathway REACTOME Pentose phosphate pathway
disease MESH ers
drug DRUGBANK Hyaluronic acid
pathway KEGG Cholesterol metabolism
pathway KEGG Tight junction
pathway KEGG Lysosome biogenesis
pathway REACTOME Gluconeogenesis
drug DRUGBANK Glycine
pathway KEGG AMPK signaling pathway
drug DRUGBANK L-Alanine
drug DRUGBANK L-Arginine
pathway KEGG Arginine biosynthesis
pathway KEGG Calcium signaling pathway
pathway KEGG Glucagon signaling pathway
pathway KEGG Histidine metabolism
pathway REACTOME TNF signaling
pathway REACTOME Apoptosis
pathway REACTOME Autophagy
pathway REACTOME Mitophagy
pathway KEGG Peroxisome
pathway REACTOME Axon guidance
pathway KEGG GABAergic synapse
pathway KEGG Serotonergic synapse
pathway KEGG Cholinergic synapse
disease MESH inflammation
disease MESH neurological disorders
disease MESH viral infection
pathway REACTOME Release
disease MESH atrophy
drug DRUGBANK Water
drug DRUGBANK Isoxaflutole
disease MESH Syndrome
disease MESH Cerebrovascular Diseases
disease MESH AIDS
disease MESH Dis
disease MESH Peripheral Neuropathies
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Infectious Diseases
pathway KEGG Viral replication
drug DRUGBANK Fenamole
drug DRUGBANK Morphine
disease MESH Anxiety Disorders
pathway REACTOME Signal Transduction
disease MESH Brain Disease
disease MESH Park
pathway REACTOME Neurodegenerative Diseases
pathway KEGG Thermogenesis
drug DRUGBANK Carboxyamidotriazole

Original Article

(Visited 9 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *